LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy.

Saved in:
Bibliographic Details
Title: LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy.
Authors: Missios P; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., da Rocha EL; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, Brazil., Pearson DS; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Philipp J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otorhinolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany., Aleman MM; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Pirouz M; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey, USA., Farache D; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Franses JW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Kubaczka C; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Tsanov KM; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Jha DK; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Pepe-Mooney B; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA., Powers JT; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Gregory RI; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.; Harvard Initiative for RNA Medicine, Boston, Massachusetts, USA., Lee AS; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Dominguez D; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Ting DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Daley GQ; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2021 Nov 15; Vol. 131 (22).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI145142